Candel Therapeutics (Nasdaq: $CADL) Stock Hub

01 The File In One Sentence: A Filing In Q4 2026, With $201.6 Million Behind It

Candel Therapeutics is a clinical-stage oncology company that has reached the part of the road most small-cap biotechs never see. It has a pivotal phase 3 trial that met its primary endpoint, published in a first-tier peer-reviewed journal, and it has told the market it plans to file a Biologics License Application in the fourth quarter of 2026. Behind that plan sits $201.6 million of cash at June 30, 2026, and a stated runway into the first quarter of 2028 that explicitly includes the cost of preparing a commercial launch in 2027.

That combination is unusual, and it is what separates this file from the general run of development-stage names. Most companies at this stage are choosing between funding the filing and funding the launch. Candel says it is funded for both.

The gap between a positive trial and an approved product is where this kind of company either becomes a commercial business or spends another two years explaining a delay. Candel has crossed the scientific part of that gap. It has not yet crossed the regulatory and manufacturing part, and the second half of 2026 is when that becomes visible.

Meanwhile the share price has already moved a long way. The stock is up 145.50% year to date and 167.77% over six months, which means a good part of the filing expectation is in the price before the filing exists. That is not an argument in either direction. It is a statement about where the burden of proof now sits.

02 Latest Verified Update — August 26, 2026

The most recent company communication is an agenda item rather than a fact about the business. On August 26, 2026 Candel announced that President and Chief Executive Officer Paul Peter Tak will take part in analyst-led fireside discussions and one-on-one meetings at three September investor conferences: Citi’s 2026 Biopharma Back to School Conference on September 9 at 10:00 a.m. Eastern, the 2026 Cantor Global Healthcare Conference on September 10 at 3:20 p.m. Eastern, and the H.C. Wainwright 28th Annual Global Investment Conference on September 15 at 9:30 a.m. Eastern. All three are webcast, with replays archived for up to 90 days.

Conference participation is not a catalyst in the sense that matters for valuation. It carries no data, no regulatory decision and no capital. It is listed here because those three dates are the only confirmed calendar dates the company currently has in front of it, and because management commentary at a Back to School or a Cantor fireside is where filing timing is often clarified before it appears in a release.

No SEC filing was made on August 26. The most recent filings are the Form 10-Q and the results Form 8-K, both dated August 13, 2026. Everything financial on this page comes from those two documents.

The stock traded at $13.87 during the session of August 26, up 1.99% against the prior close of $13.60, on a market capitalisation of about $1.06 billion. Stocktwits ranked $CADL thirteenth by message volume that morning, with message activity up roughly 57% over the week and a retail sentiment reading of 99.46% bullish. That last number is a positioning fact, not a company fact, and it is discussed in the ownership section below.

A note on what the retail flow is discussing. A large share of the current commentary concerns a possible expansion of the HSV programme into triple-negative breast cancer, with market-size estimates attached. No company communication reviewed for this page mentions triple-negative breast cancer. The HSV lead is in a phase 1b trial in recurrent high-grade glioma, and the company’s stated next step for it is a potential randomised phase 2 dose-regimen-finding study in recurrent glioblastoma. The distinction is worth holding onto.

03 Executive Summary

Candel develops off-the-shelf multimodal viral immunotherapies designed to turn the destruction of a tumour into an immunological event. The strategy is in-situ immunisation: kill tumour cells in a way that releases their antigens under inflammatory conditions, so the immune system learns to attack the same tumour elsewhere in the body, including lesions that were never injected.

Two clinical-stage platforms carry that idea, and they are not equally advanced.

• The adenovirus platform is led by aglatimagene besadenovec, formerly CAN-2409. It is a replication-defective adenovirus that delivers the herpes simplex virus thymidine kinase gene into the tumour. The enzyme then converts the prodrug valacyclovir into nucleotide analogues that incorporate into DNA, producing immunogenic cell death in dividing and damaged cells. The adenoviral capsid itself drives inflammation. More than 1,000 patients have been dosed with it. This is the pillar.
• The HSV platform is led by linoserpaturev, formerly CAN-3110, a replication-competent oncolytic herpes simplex virus designed to do both oncolysis and immune activation in one agent. It is in a phase 1b trial in recurrent high-grade glioma, with results in Nature in 2023 and a biopsy analysis in Science Translational Medicine in October 2025. This is optionality, not a pillar.

The prostate programme is the whole near-term story. The randomised, double-blind, placebo-controlled pivotal phase 3 in localized intermediate- to high-risk prostate cancer was published in The Lancet Oncology, showing a statistically significant improvement in disease-free survival for aglatimagene plus standard-of-care radiotherapy against radiotherapy alone. The FDA has granted Fast Track and Regenerative Medicine Advanced Therapy designations in that indication, and the trial ran under a Special Protocol Assessment. A BLA is planned for the fourth quarter of 2026, with a potential launch in 2027 if approved.

The lung programme is what decides whether this is a platform or a product. In June 2026 Candel activated the first site of AURORA, a global pivotal phase 3 in metastatic non-squamous NSCLC that has progressed despite pembrolizumab and platinum chemotherapy. The design is open-label, randomised one-to-one across roughly 150 sites, comparing aglatimagene plus valacyclovir on top of continued pembrolizumab against standard-of-care docetaxel. The primary endpoint is overall survival.

The balance sheet is the strongest part of the file and it did not come free. Cash went from $119.7 million at the end of 2025 to $201.6 million at June 30, 2026, on the back of a February follow-on that sold 18,348,624 shares at $5.45. Weighted-average shares rose from 51.5 million in the second quarter of 2025 to 74.1 million in the second quarter of 2026. Runway is guided into the first quarter of 2028.

And there is a piece of capital that only exists if the FDA says yes. Under a February 2026 agreement, funds managed by RTW Investments will pay Candel $100 million on marketing approval of aglatimagene in intermediate- and high-risk localized prostate cancer, in exchange for a tiered royalty on future U.S. net sales. That structure converts approval into cash without issuing shares, and it also means a share of the commercial upside has already been sold.

04 The Platform: What These Two Viruses Actually Do

Oncology investors have seen a long procession of interesting mechanisms that did not survive contact with real disease. It is worth being precise about what Candel’s two constructs do, because the two are often discussed as if they were the same thing.

Aglatimagene besadenovec: a delivery vehicle, not an oncolytic

Aglatimagene is replication-defective. It does not multiply inside the tumour and it does not kill cells by lysing them. Its job is to carry one gene, herpes simplex virus thymidine kinase, into tumour cells. Once the enzyme is being expressed, the patient takes valacyclovir, an ordinary antiviral. The enzyme converts it into nucleotide analogues that get incorporated into DNA, and cells that are dividing or already carrying DNA damage die in a way that is immunologically visible rather than silent.

Two things follow from that design. First, the tumour cells that die release a broad set of antigens, including neoantigens specific to that patient’s tumour, into an environment that the adenoviral capsid proteins have already made inflammatory by inducing cytokines, chemokines and adhesion molecules. Second, because it depends on radiotherapy, surgery, chemotherapy or checkpoint inhibition to create the DNA damage it exploits, aglatimagene is designed to be given on top of standard of care, not instead of it. Every pivotal trial in the programme is structured that way.

Linoserpaturev: the opposite construction

Linoserpaturev is replication-competent. It is a next-generation oncolytic HSV-1 built to do two jobs in one agent: lyse tumour cells directly, and activate an immune response while doing it. That makes it more potent in principle and more demanding on safety, which is why it sits in a phase 1b trial and why the next planned step is a dose-regimen-finding study rather than a pivotal.

Behind both sits enLIGHTEN, the company’s HSV-based discovery platform, described as a systematic and iterative engine for generating new viral immunotherapies for solid tumours. It has produced no clinical candidate that the company has put a name and a trial to, and it should be read as a research asset rather than as pipeline.

Why the distinction matters commercially. A replication-defective gene-delivery product with more than 1,000 patients dosed and a favourable tolerability record is a manufacturing and logistics problem with a known shape. A replication-competent oncolytic virus is a different regulatory conversation. Treating the two as one platform, as the enthusiastic version of this story sometimes does, overstates how much of the risk has been retired.

05 The Prostate Phase 3: What Was Measured And What It Showed

The trial that carries this company was randomised, double-blind, placebo-controlled and multicentre, in patients with localized, intermediate- to high-risk prostate cancer. Patients received aglatimagene plus standard-of-care radiotherapy, or placebo plus the same radiotherapy. It enrolled 745 patients. Results were first announced in December 2024, presented as an oral at ASCO in 2025, and published in The Lancet Oncology in 2026.

The published finding is a statistically significant improvement in disease-free survival for the aglatimagene arm against radiotherapy alone. Two features of the trial’s construction are worth more attention than they usually get.

• It ran under a Special Protocol Assessment. An SPA is a written agreement with the FDA on aspects of trial design, endpoints and analysis reached before the trial reads out. It does not guarantee approval and it does not bind the agency if new issues arise, but it substantially narrows the range of arguments available later about whether the study asked the right question.
• The comparator is standard of care, not nothing. Both arms received radiotherapy. The measured benefit is incremental on top of the treatment these patients would have received anyway, which is the harder and the more commercially relevant comparison.

The regulatory designations are supportive, not decisive. The FDA has granted aglatimagene Fast Track Designation and Regenerative Medicine Advanced Therapy designation in newly diagnosed localized prostate cancer at intermediate to high risk. RMAT brings the possibility of more frequent interaction with the agency and eligibility for priority review and accelerated approval, but neither designation is an approval, and neither shortens the manufacturing work described in the next section.

What is not established. Disease-free survival is not overall survival. A prostate cancer population at intermediate to high risk has a long natural history, and the endpoint that ultimately matters to payers and physicians is whether patients live longer, not only whether their disease stays away longer. The company has not claimed an overall-survival benefit and this page does not imply one.

06 The AUA 2026 Extended Follow-Up, Read Precisely

On May 15, 2026 the company presented extended follow-up from the same phase 3 in a plenary oral presentation at the American Urological Association Annual Meeting in Washington, D.C., held May 15 to 18. A plenary slot at the AUA is the field’s main stage, and that placement is itself a signal about how the urology community reads the data.

The headline figure is a 39% improvement in prostate cancer-specific disease-free survival against placebo, after a median follow-up of 58 months, with a data cut-off of March 15, 2026. Nearly five years of median follow-up on a 745-patient randomised trial is a substantial evidence base by the standards of this sector.

The company also reported consistently favourable trends against placebo, in both the intent-to-treat population and the intermediate-risk subgroup, across every secondary and exploratory endpoint it listed:

• time to biochemical failure;
• time to metastasis;
• rate of metastasis;
• time to salvage anti-cancer therapy, that is, time to the next treatment.

It stated that no new safety signals or additional toxicities were observed.

A further analysis is scheduled. The company said it will present an abstract on extended biomarker data from the same phase 3 as a poster at the ASTRO Annual Meeting in the third quarter of 2026. Biomarker work matters here for a specific commercial reason: if a marker can identify which patients respond, it changes both the label conversation and the price conversation.

07 From Data To Filing: The Manufacturing Work That Gates The BLA

The single most under-discussed item on this file is chemistry, manufacturing and controls. The company is explicit about it, and it deserves to be read at face value.

Candel states that it continues to advance pre-BLA readiness across CMC activities, preparation of clinical study reports and BLA modules, and that a process validation campaign for drug substance and drug product is being executed at its contract development and manufacturing organisation. Its own words: the campaign “is progressing well and is a critical CMC activity to enable the anticipated BLA submission in Q4 2026”.

That sentence is the gating item for the entire near-term thesis. A biologics licence application is not a clinical dossier with a manufacturing appendix. For a viral vector product the CMC section is a large fraction of the filing and a common source of delay and of complete response letters, and process validation at a third-party manufacturer is the step where a schedule slips without anything being wrong with the science.

Three specifics are worth tracking as this progresses:

• The campaign is at a CDMO, not in-house. That is capital-efficient and it is normal at this size, and it also means the timeline depends on a partner’s capacity and on comparability between batches.
• New clinical material has been produced and is intended for the pivotal NSCLC trial. Producing material for AURORA while validating process for a prostate filing puts two demands on the same manufacturing chain in the same window.
• Q4 2026 is a window, not a date. No FDA-assigned date exists until the agency accepts a filing, and acceptance itself typically follows submission by around two months. Anyone modelling an approval decision should start the clock at acceptance, not at submission.

If the filing goes in during the fourth quarter and is accepted, the review timetable that follows becomes the first hard date this company has ever had. Until then, everything on the regulatory side is company guidance.

08 AURORA: The Lung Trial That Decides Whether This Is A Platform

In June 2026 Candel activated the first clinical trial site and opened enrolment for AURORA (NCT07660094), a global pivotal phase 3. The design, as disclosed:

• Population: metastatic stage IV non-squamous non-small cell lung cancer whose disease has progressed despite treatment with pembrolizumab and platinum-based chemotherapy.
• Experimental arm: two courses of aglatimagene plus valacyclovir, with continued pembrolizumab.
• Control arm: standard-of-care docetaxel chemotherapy.
• Randomisation: one to one, open-label, across approximately 150 sites worldwide.
• Primary endpoint: overall survival. Secondary endpoints include safety and quality of life, measured with NSCLC-SAQ and EORTC QLQ-30.

The choice of setting is the interesting part. Patients who progress after a checkpoint inhibitor and platinum chemotherapy are a population where the field has repeatedly failed, and where docetaxel remains the comparator precisely because nothing better has established itself. A trial that beats docetaxel on overall survival in that setting would be commercially significant on its own terms, and it would also be the clearest possible demonstration that the in-situ immunisation mechanism transfers from one tumour type to another.

The design is honest and it is demanding. Overall survival as the primary endpoint, in a global randomised trial, is the hardest evidence to generate and the hardest to argue with. It is also slow, expensive and unforgiving. An open-label design with a chemotherapy comparator introduces the usual questions about quality-of-life reporting, and 150 sites is a large operational undertaking for a company of this size.

What to watch is enrolment, not data. No readout timing has been disclosed and none should be assumed. For the next several quarters the meaningful AURORA news is the pace at which sites activate and patients enrol, because that is what determines whether the trial reads out on a schedule that the current balance sheet can reach. The FDA has previously granted aglatimagene Fast Track Designation in NSCLC.

09 Linoserpaturev In Recurrent Glioblastoma: Real Optionality, Early Stage

The HSV programme is where the science is most striking and the clinical position is weakest, and both halves of that sentence are true at once.

Linoserpaturev is in an ongoing phase 1b trial in recurrent high-grade glioma. Results published in Nature in 2023 reported that it was generally well tolerated with no dose-limiting toxicity, and that investigators observed improved median overall survival compared with historical controls after a single injection in a therapy-resistant condition. Historical-control comparisons are the weakest form of survival evidence and should be read as hypothesis-generating.

The more recent work is about mechanism rather than outcome. In October 2025 Science Translational Medicine published a comprehensive analysis of 97 serial tumour biopsies collected from two patients treated with repeated administrations in arm C of the trial. Ninety-seven biopsies from two patients is an extraordinary depth of sampling in a disease where tissue is very hard to obtain, and it is the kind of dataset that explains a mechanism rather than proving a benefit. The company and its academic collaborators are supported in this work by the Break Through Cancer foundation.

Where the programme stands now. The FDA cleared an Investigational New Drug application for linoserpaturev in the first quarter of 2026. The company says enabling work is underway to support a potential randomised phase 2 dose-regimen-finding study in recurrent glioblastoma, intended to establish the optimal number of administrations and a recommended regimen for future development. The word to notice is “potential”: the study has not been announced as initiated.

One dated item does sit here. The company expects to present potential long-term survival data from arm C of the phase 1b in the fourth quarter of 2026. That is the same quarter as the planned prostate filing, and it is the only clinical readout currently guided for this year.

Linoserpaturev holds Fast Track Designation and Orphan Drug Designation for recurrent high-grade glioma. Orphan designation carries real economic value on approval, including a period of market exclusivity, and it applies to a programme that is several years and at least two trials away from a filing.

10 Financial Position At June 30, 2026

The second-quarter balance sheet is the strongest this company has ever presented, and the income statement is the heaviest. Both facts have the same cause.

The figures are internally consistent: total assets less warrant liabilities and other liabilities equals stockholders’ equity to the thousand, at both dates, and the movement in accumulated deficit equals the six-month net loss exactly.

Runway. The company states that cash at June 30 is expected to fund the current operating plan into the first quarter of 2028, and that this plan already includes activities to support a potential U.S. commercial launch of aglatimagene in 2027. That is a meaningfully different statement from a runway that funds development only, and it is the reason this file does not carry the going-concern language that dominates most names of comparable size.

The obvious arithmetic, and its limits. Second-quarter operating expenses were $26.7 million. Taken flat, $201.6 million is about seven and a half quarters, which lands in the first quarter of 2028 and matches the guidance. The reason to hold that loosely is that the spend is not flat: a BLA filing, a 150-site global phase 3 and pre-launch commercial build are all ramping at once, and the trend in the cost line says so.

11 What The Cost Line Is Telling You

Operating expenses are the most informative series on this file, because they show a company changing from a clinical operation into one preparing to sell something.

Research and development in the second quarter was $19.8 million, against $7.0 million a year earlier. General and administrative was $6.9 million, against $4.2 million. The company attributes the R&D increase to higher clinical trial and manufacturing costs supporting the aglatimagene programmes and higher employee costs, and the G&A increase primarily to higher commercial readiness costs and employee costs.

Stock compensation inside those figures was $1.8 million in R&D and $1.0 million in G&A for the quarter, against $0.4 million and $0.6 million a year earlier. So $2.8 million of the $26.7 million is non-cash.

Reconstructing the quarters from the six-month totals the company published gives the shape of the ramp:

Spending has more than doubled year on year in each of the last two quarters, and the second-quarter step is larger than the first. This is what a company looks like when it is running a pivotal trial, validating a manufacturing process and building a commercial function at the same time. It is also the reason the runway guidance deserves to be re-checked at every quarterly release rather than assumed.

The net loss needs a separate explanation. Net loss for the quarter was $38.9 million, against an operating loss of $26.7 million. The gap is almost entirely a $12.3 million non-cash charge for the change in fair value of warrant liabilities. Warrant liabilities are remeasured every quarter against the share price: when the stock rises, the liability rises and the income statement takes a charge. A stock that has roughly doubled since the spring therefore produces a larger reported loss. It costs no cash and it says nothing about operations, and it is the single most misread line on this file.

12 Capital Structure, Dilution And The Money That Only Arrives On Approval

Candel funded this year in three distinct ways, and only one of them issued shares.

The February 2026 follow-on

The company sold 18,348,624 shares at $5.450, for gross proceeds of $100.0 million. Underwriting discounts were $0.327 a share, leaving $5.123 a share before expenses, and the company estimated net proceeds of approximately $93.5 million. Shares outstanding immediately after the offering were 73,244,473, rising to 75,996,766 if the underwriters exercised their option over a further 2,752,293 shares in full. Finviz reports 76.12 million shares outstanding today, which is consistent with that option having been taken up.

The dilution is visible in the weighted-average count: 51,489,929 shares in the second quarter of 2025 against 74,131,229 in the second quarter of 2026, an increase of about 44%. The offering was priced at $5.45 when the last reported sale price was $5.85, a discount of about 6.8%.

The Trinity term debt

The company carries term debt under a Loan and Security Agreement with Trinity Capital and other lenders, with warrants over 254,642 shares at a $5.89 exercise price issued to the lenders. Interest expense was $1.6 million in the quarter, against $0.2 million a year earlier. Debt at this stage is capital that does not dilute today and does constrain later: the company’s own risk language flags its ability to access future tranches and to comply with its obligations under the facility.

The RTW royalty agreement, and why it is the most interesting item here

On February 19, 2026 Candel entered a purchase and sale agreement with funds managed by RTW Investments. Under it, RTW will pay Candel $100 million upon FDA marketing approval of aglatimagene in intermediate- and high-risk localized prostate cancer, in exchange for a tiered royalty on future U.S. net sales:

• 4.67% on the portion of annual U.S. net sales at or below $1 billion;
• 1.33% on the portion above $1 billion;
• the 4.67% tier ratchets to 6.67% if annual net sales do not reach specified levels, subject to a cure opportunity, and both the ratchet and the cure can occur more than once;
• royalties begin after first commercial sale and end once RTW has received $250 million, the royalty cap;
• a buy-out option lets Candel terminate by paying specified amounts on a change of control or a sale of the product, up to the cap.

The transaction is subject to closing conditions, including that FDA approval occurs by a specified date and conditions relating to the company’s indebtedness.

13 Market Data, Ownership And Positioning

Figures from Finviz at the August 26, 2026 reading, except where stated.

The performance record is the context for everything above. Up 2.75% on the week, 43.29% on the month, 72.31% on the quarter, 167.77% over six months, 145.50% year to date and 132.73% over one year. Over three years the stock is up 971.10%.

Three ownership facts that pull against each other. Institutional ownership at 62% is unusually high for a billion-dollar clinical-stage company and says that professional money has underwritten the prostate thesis. Insider ownership at nearly 21% aligns management with the outcome. And short interest at 20.60% of float says a substantial group is positioned for the filing to slip, the approval to fail, or the valuation to prove early.

A short base that size changes how the stock behaves rather than what the company is worth. Positive news is amplified by covering, and disappointing news arrives into an audience that is already positioned for it. Neither effect is information about aglatimagene.

Retail sentiment, with the usual warning. Stocktwits showed $CADL thirteenth by message volume on the morning of August 26, with weekly message activity up about 57% and a sentiment reading of 99.46% bullish against 0.54% bearish. These are the opinions of non-professional traders, not analysts, and a reading that one-sided is a description of crowding rather than of merit. It is worth remembering that a large part of that conversation concerns a breast-cancer expansion the company has not announced.

14 Catalyst Map

15 The Two Cases As Their Holders Put Them

The constructive case

A 745-patient randomised, double-blind, placebo-controlled phase 3 run under a Special Protocol Assessment met its primary endpoint and was published in The Lancet Oncology. Extended follow-up at a median of 58 months showed a 39% improvement in prostate cancer-specific disease-free survival with no new safety signals, presented in a plenary slot at the AUA. Fast Track and RMAT are in hand. A BLA is planned for the fourth quarter, a commercial chief with 25 years of oncology launch experience has been hired, and EVERSANA provides commercial infrastructure without the fixed cost of building it. Behind all of that sits $201.6 million of cash, a runway into the first quarter of 2028 that already includes launch spending, and $100 million more that arrives on approval without issuing a share. Meanwhile AURORA gives a second, larger indication a real shot on goal with overall survival as the endpoint, and the HSV platform sits underneath as unpriced optionality.

The sceptical case

There is no approved product and no product revenue, and the filing that would begin to change that has not been made. The company’s own gating item is a manufacturing validation campaign at a third-party site, which is exactly where schedules slip. Disease-free survival is not overall survival, and in a disease with a long natural history the payer conversation will be harder than the clinical one. The stock has already risen 145% this year and carries a billion-dollar valuation on a pre-filing asset, which means the filing is largely in the price and a slip is not. Operating expenses have more than doubled year on year for two consecutive quarters, so the runway is a moving target. The share count is up 44% year on year, up to $250 million of future U.S. royalties has already been sold to RTW, and 20.60% of the float is short. AURORA is early, expensive and years from data, and the HSV programme is a phase 1b with a two-patient biopsy study as its most recent publication.

Both descriptions are built from the same disclosures. The distance between them is a question about execution over the next three to six quarters, not a disagreement about the facts.

16 Red Flags And What Would Change The Picture

• The BLA is a company window, not an agency date. Q4 2026 has no regulatory force. The clock only starts when the FDA accepts a filing, and acceptance normally comes about two months after submission.
• CMC is the stated gate and it sits at a third party. The process validation campaign for drug substance and drug product is running at a contract manufacturer. Comparability, capacity and batch performance are outside the company’s direct control.
• Two demands on one manufacturing chain. New clinical material for the NSCLC pivotal is being produced while validation for the prostate filing proceeds.
• The cost base is compounding. Operating expenses of $26.7 million in the quarter, more than double a year earlier, with the second-quarter step larger than the first. Runway guidance is only as good as the spend assumption behind it.
• Reported losses will look worse when the stock does well. The $12.3 million warrant remeasurement is non-cash and moves with the share price. Anyone reading net loss without adjusting for it will misjudge the burn.
• Royalty sold before revenue exists. Up to $250 million of U.S. economics is committed to RTW, with a ratchet that raises the rate if sales disappoint.
• Positioning is crowded on both sides. Short interest at 20.60% of float against retail sentiment at 99.46% bullish is an unstable combination around any binary event.
• Endpoint translation risk. A disease-free survival benefit has to survive the conversation about whether it changes how long and how well patients live.

What would strengthen the file: the BLA submitted within the guided window and accepted for review; the ASTRO biomarker data identifying a responder population; AURORA enrolment running to plan; and an operating expense line that stabilises rather than steps up again.

What would weaken it: any slip in the filing window attributed to CMC; a complete response letter on manufacturing after submission; equity issued below the February price; a slower AURORA than the site count implies; or a third quarter that raises the spend again without extending the runway statement.

17 Merlintrader Health Score

The Merlintrader Health Score is a one-to-five reading of financial and operational robustness over the next twelve to eighteen months, built on five weighted pillars. It measures how much shock a company can absorb, not whether a share is worth buying, and it is not an indication to buy or sell.

Weighted result: 3.8 out of 5. A well-funded company with a dense catalyst calendar and a real late-stage asset, held back mainly by a dilution record that has been the price of that funding, and by the fact that its central near-term event is still a plan rather than a date.

18 Merlintrader Bottom Line

Candel has done the hard part. A randomised, placebo-controlled phase 3 in 745 patients, run under an agreement with the FDA on its design, met its primary endpoint and has been published where the field will read it. Extended follow-up at nearly five years strengthened rather than eroded the finding. That is a level of evidence most companies of this size never reach.

What remains is the part that does not make headlines. A biologics licence application has to be assembled, a manufacturing process has to be validated at a contract site, and a filing has to be accepted before any clock starts running. The company has said the fourth quarter of 2026, and it has told the market plainly that the validation campaign is the critical activity enabling that. Those two sentences are the whole near-term file.

The financing has been handled with more imagination than most. An equity raise at a modest discount, term debt, and a royalty sale that delivers $100 million precisely at approval, together fund development and a launch out to the first quarter of 2028. The cost is a 44% larger share count, up to $250 million of future U.S. sales committed away, and a spend line that has more than doubled year on year for two quarters running.

The market has already repriced the story: up 145% this year, a billion dollars of capitalisation, 62% institutional ownership and 20.60% of the float short. That mix means the next few disclosures will be read hard in both directions.

The reasonable way to follow this file from here is narrow. Watch whether the BLA goes in within the guided window and is accepted; watch the ASTRO biomarker data for a responder signal; watch AURORA enrolment; and watch the operating expense line at the third-quarter release, because it is the number that decides whether the runway statement still holds.

Related Research On Merlintrader

• Biotech Stock Hubs index — every biotech hub on Merlintrader, with the date each was last verified.
• Top Ten Biotech Stocks Right Now — the ten names we are watching most closely.
• Free Biotech Catalyst Calendar — PDUFA dates, advisory committees and clinical readouts.